TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Study Drug Adherence by sleep diary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Study Drug Adherence by serum or sweat assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of qXR LNMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Negative predictive value of qXR LNMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accidental Awareness During General Anesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: fMRI measures of functional activation in the fear extinction network
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: fMRI measures of functional activation in the whole brain neural connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Epworth sleepiness scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in QIDS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Treatment failure defined by use of rescue respiratory support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Progression to PDR and/or CI-DME
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percentage of Participants Achieving a rating of much better or very much better
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Type of ventilation used in pre-hospital care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ventilatory settings used in pre-hospital care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pre-hospital intervention duration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: meniscal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HU-PK evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of linezolid-induced thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Identification of Pancreatic Cancer Risk Groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Success rate of rectosigmoidoscopic procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Survey response rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Objective measure of cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Albendazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Curve From Time 0 to the Last Measured [AUC(0-t)] for Albendazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants who Achieve Endoscopic Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of puncture needles used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Neck Proprioception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Disease Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence rate of persistent LBBB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of duration of 10 Meters Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of duration of Time Up and Go
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-hour energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 24-hour RQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rsFC changes in hippocampal networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection of tumor in MRI-negative cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor Necrosis Factor Alpha Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleuken 6 Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinician Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional Assessment of Cancer Therapy (FACT)-Leukemia total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disease control rate (DCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progression-free survival in rapid early responder patients
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free survival in slow early responder patients
Endpoint domain: Mortality/survival
Primary endpoint: Skin-to-subdural/epidural distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Needle depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Difference in bodyweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients who are circulating tumor DNA negative (ctDNA[-])
Endpoint domain: Mortality/survival
Primary endpoint: Fugl-Meyer Assessment Lower Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kessler Psychological Distress Scale 6 (K6)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of PF-07817883
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-07817883
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BBS prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electronic patient-reported outcome (ePRO) confirming treatment initiation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Subjects Who Achieved the Primary Composite Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of confirmed TB cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean change in loneliness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in PCP Chiropractor Referrals for LBP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Suppression of ovarian function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of germline testing, liquid biopsy and whole body magnetic resonance imaging
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recommended Phase II dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of subjects who achieve normalization of ALP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type and frequency of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: BCVA - 15-letter improvement (3-line gain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pudendal nerve function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional recovery at visit 3
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: days alive and out of hospital at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Maternal body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Lactation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in NPI-C: H+D score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mini-Mental State Examination (MMSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clinical Dementia Rating (CDR) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Numerical Rating Scale - NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Form - 36 Quality of Life Questionnaire (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Temporomandibular disorders function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mandibular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean Percent Change in Apolipoprotein A-I (ApoA-I) in Cerebrospinal Fluid (CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Change in Apolipoprotein A-I (ApoA-I) in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Change in Apolipoprotein-E (ApoE) in Cerebrospinal Fluid (CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Change in Apolipoprotein-E (ApoE) in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of treatment in reducing atrophic acne scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of Participants with Remission of ir-colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Items Recalled in CWMS Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI measure in CWMS Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance in Effort Expenditure for Reward Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance in Card-Guessing fMRI task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Zibrio SmartScale measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Term Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Long Term Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of doses taken by participants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Moderate-to-severe headache day frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving sustained remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parenting behavior
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Parenting self-efficacy in labor
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Spouse support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Father candidates' attitudes towards participating in birth
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Firefighters and Fire Stations Recruited to the Study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Firefighters Retained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Sessions Attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tumor response as measured by RECIST v1.1 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of ultrasound imaging for tracking joint kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of youth initiating psychotherapy
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percentage of subjects experiencing neurological death or major ipsilateral stroke
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of subjects with 100% occlusion (Raymond Class 1) without clinically significant stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of participants with subsequent goals of care conversation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Reporting Breast Pain
Endpoint domain: Adverse events/effects
Primary endpoint: monitoring remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mother sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Monthly rates of blood smear positive individuals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in total tenderness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in muscle pressure pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mandibular condyle changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% Prostate-Specific Antigen Response Rate (PSA-RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: surgical risk prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from Baseline in Autism Behavior Inventory (ABI)-Social Communication Domain Score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Percentage of Participants who Experience Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants who Experience an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants who Discontinue Study Intervention Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Ability to detect anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety and Tolerability assessed by Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained reconstitution of NADPH oxidase activity in neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean proportion of criterion correctly abstracted by AI-augmented human reviewers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean proportion of criteria correctly abstracted by human-alone reviewers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants no longer meeting diagnostic criteria of post-COVID POTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants who Achieve Thyroid-Stimulating Hormone (TSH) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of confirmed, adjudicated VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of participants who die or progress to IMV/ECMO
Endpoint domain: Mortality/survival
Primary endpoint: Change in microRNA expression profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preclinical Alzheimer's Cognitive Composite (PACC) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sublingual microcirculation profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ADAS-Cog 13 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in levels of CSF biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in levels of serum biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time spent in glucose target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time spent below the target glucose range
Endpoint domain: Adverse events/effects
Primary endpoint: Complete response for cytokine release syndrome (CRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Successful en-bloc tumour resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in microbiome species
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased Hope
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ CSS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of adverse events of dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Overall response rate (ORR) as assessed by the investigator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in glycemic Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrence free and overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Involved resection margins in the final histopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of re-excisions during breast conserving surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Global performance composite score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Consciousness fluidity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Objective responses rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with no antibiotic related adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Ureter conspicuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: changes in insomnia symptoms
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: prevention of perinatal depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neutralizing antibody activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients receiving guideline-concordant care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants reporting adverse events (AE) and serious adverse event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Torticollis Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of cardiotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in COLLABORATE scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment acceptability
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rescored modified International Cooperative Ataxia Rating Scale (RmICARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NLRP3 gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-18 gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-18 cytokine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-1b cytokine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mood regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frontostriatal Activation Associated with Prediction Errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frontostriatal Activation Encoding the Subjective Value of Cognitive Effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Relapse rate of Haemophilus influenzae pneumonia
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With MIRV-related Corneal AEs (≥ Grade 2)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence proportion of hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: End Expiratory Lung Impedance (EELI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Invasive Breast Cancer Free Survival (iBCFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Post operative pain incidence and intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with one or more adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: microvascular acetylcholine-mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes